Multimodal study of cognitive impairment following radiation therapy for locally advanced head and neck cancer
局部晚期头颈癌放射治疗后认知障碍的多模式研究
基本信息
- 批准号:10656212
- 负责人:
- 金额:$ 25.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ABCB1 geneAddressAdjuvant TherapyAdultAftercareAreaBiometryBlood - brain barrier anatomyBrainBrain regionCancer SurvivorCandidate Disease GeneCase SeriesCerebellumCharacteristicsChildClinicalClinical Trials DesignCognitionCognitiveCognitive remediationComplicationCoupledCranial IrradiationCross-Sectional StudiesDNA RepairDevelopmentDevelopment PlansDiagnosisDiseaseDoseDrug TransportERCC3 geneEpidemiologyExposure toFoundationsFutureGenesGenetic Predisposition to DiseaseGenetic VariationGerm-Line MutationGoalsHead and Neck CancerImpaired cognitionImpairmentIndividualInferiorIntensity modulated proton therapyInterventionInvestigationLate EffectsLocal TherapyLong-Term SurvivorsMalignant NeoplasmsMeasuresMemoryMentorsModernizationMolecularMolecular EpidemiologyMorbidity - disease rateMotorNasopharyngeal NeoplasmsNeurocognitiveNeuropsychologyNormal tissue morphologyOperative Surgical ProceduresOrganOropharyngeal NeoplasmsOutcomePatient Outcomes AssessmentsPatientsPatternPerformancePersonsPhotonsPlanning TechniquesPopulationProcessPrognosisProton RadiationQuality of lifeQuestionnairesRadiationRadiation Dose UnitRadiation exposureRadiation therapyRadiometryReportingResearchResearch MethodologyResearch PersonnelRiskRisk ReductionScientistSeveritiesSingle Nucleotide PolymorphismSiteStandardizationStatistical ModelsTechniquesTemporal LobeTrainingTreatment FactorXRCC1 geneadvanced diseasebrain volumecancer therapycareercareer developmentchemotherapeutic agentchemotherapycognitive functioncognitive testingcohortdrug metabolismexperiencegenetic associationgenetic varianthead and neck cancer patienthigh riskimprovedmultimodalityneural repairneurocognitive testneurological rehabilitationneurotransmissionpatient populationradiation effectradiation riskskillssuccesssurvivorshiptreatment planning
项目摘要
PROJECT SUMMARY
Treatment of locally advanced head and neck cancer (LAHNC) commonly entails the use of radiation
therapy, which often exposes portions of the brain, particularly the cerebellum and inferior temporal lobes, to
moderately high doses of radiation. The negative effects of cranial radiation exposure on cognition are well
established in other types of malignancies, but remain unstudied in LAHNC patients. The underlying disease
process, chemotherapeutic agents, and radiation dose distribution in patients treated for LAHNC are
fundamentally different from the patient populations previously studied, suggesting that patterns of cognitive
impairment may also differ. This scientific proposal will elucidate the cognitive effects of radiation in LAHNC
patients through three specific aims. Scientific Aim 1 will characterize the cognitive profiles of LAHNC survivors
by administering a neuropsychological battery and patient questionnaires. Radiation dosimetry to individual
regions of the cerebellum and temporal lobes will be calculated from the original treatment plans. The effects of
patient and treatment characteristics (including chemotherapy exposure and radiation dosimetry) on post-
treatment cognition will be assessed. Scientific Aim 2 will determine the association between cognitive
impairment and germline variants. Germline single nucleotide polymorphisms will be determined using a
biologically-plausible, carefully curated candidate gene approach and assessed for association with the
neurocognitive battery results. Scientific Aim 3 will explore how modern radiation planning techniques can be
utilized to reduce brain radiation exposure for LAHNC treatment. Comparison radiation plans will be generated
using Multi-Criteria Optimized intensity modulation and proton therapy. This study will promote my long-term
career goal of improving quality of life for patients who received radiation therapy and will provide opportunities
for additional training and career development. The career development plan includes training in biostatistical
and research methodology, normal tissue complication probability modeling, and fundamentals of molecular
epidemiology and cognitive assessment. The scientific and training plans are supported by a team of
experienced mentors and advisors who are committed to the success of this project and my development as a
clinician scientist. The primary mentor is an expert in neurocognitive outcomes among cancer survivors, an
experienced mentor of young investigators, and the director of the UAB Institute for Cancer Outcomes and
Survivorship. The results of this proposal will be utilized to form the foundation of a future clinical trial designed
to reduce cognitive morbidity in LAHNC patients by identifying those patients at highest risk for cognitive
impairment, maximally reducing brain radiation exposure, and implementing a tailored cognitive remediation
intervention. This project will strengthen my skills as a clinical researcher, establish an independent research
platform, and make a true contribution towards improving clinical outcomes in cancer survivors.
项目概要
局部晚期头颈癌 (LAHNC) 的治疗通常需要使用放射治疗
治疗经常暴露大脑的某些部分,特别是小脑和下颞叶,
中等高剂量的辐射。颅脑辐射暴露对认知的负面影响是显而易见的
已在其他类型的恶性肿瘤中建立,但尚未在 LAHNC 患者中进行研究。基础疾病
LAHNC 治疗患者的治疗过程、化疗药物和放射剂量分布
与之前研究的患者群体有根本不同,这表明认知模式
损害也可能不同。这项科学提案将阐明辐射对 LAHNC 认知的影响
患者通过三个具体目标。科学目标 1 将描述 LAHNC 幸存者的认知概况
通过管理神经心理学电池和患者问卷调查。个人辐射剂量测定
小脑和颞叶的区域将根据原始治疗计划进行计算。的影响
术后患者和治疗特征(包括化疗暴露和放射剂量测定)
将评估治疗认知。科学目标 2 将确定认知之间的关联
损伤和种系变异。种系单核苷酸多态性将使用
生物学上合理的、精心策划的候选基因方法,并评估其与
神经认知电池结果。科学目标 3 将探索现代辐射规划技术如何
用于减少 LAHNC 治疗时的脑部辐射暴露。将生成比较辐射计划
使用多标准优化强度调制和质子治疗。这项研究将促进我的长期
提高接受放射治疗的患者的生活质量的职业目标,并将提供机会
以获得额外的培训和职业发展。职业发展计划包括生物统计培训
和研究方法、正常组织并发症概率模型以及分子生物学基础
流行病学和认知评估。科学和培训计划得到了团队的支持
经验丰富的导师和顾问致力于该项目的成功以及我作为一个人的发展
临床医生科学家。主要导师是癌症幸存者神经认知结果方面的专家,
经验丰富的年轻研究者导师,UAB 癌症结果研究所所长
幸存者。该提案的结果将用于构成未来设计的临床试验的基础
通过识别认知风险最高的患者来降低 LAHNC 患者的认知发病率
损伤,最大限度地减少大脑辐射暴露,并实施量身定制的认知补救措施
干涉。这个项目将增强我作为临床研究员的技能,建立独立的研究
平台,并为改善癌症幸存者的临床结果做出真正的贡献。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A focused review of statistical practices for relating radiation dose-volume exposure and toxicity.
- DOI:10.1186/s13014-023-02220-9
- 发表时间:2023-03-24
- 期刊:
- 影响因子:3.6
- 作者:McDonald, Andrew M.;Schneider, Craig S.;Stahl, John M.;Oster, Robert A.;Popple, Richard A.;Mayo, Charles S.
- 通讯作者:Mayo, Charles S.
Factors associated with loss to follow-up after radiation therapy for head and neck cancer.
- DOI:10.1002/hed.26986
- 发表时间:2022-04
- 期刊:
- 影响因子:0
- 作者:Hoyle JM;Correya TA;Kenzik K;Francisco L;Spencer SA;Willey CD;Bonner JA;Snider JW;Boggs DH;Carroll WR;Bhatia S;McDonald AM
- 通讯作者:McDonald AM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew M McDonald其他文献
Andrew M McDonald的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew M McDonald', 18)}}的其他基金
A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
氟班色林在接受雄激素抑制治疗前列腺癌的男性中的随机 II 期试验
- 批准号:
10195766 - 财政年份:2021
- 资助金额:
$ 25.4万 - 项目类别:
A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
氟班色林在接受雄激素抑制治疗前列腺癌的男性中的随机 II 期试验
- 批准号:
10407479 - 财政年份:2021
- 资助金额:
$ 25.4万 - 项目类别:
Multimodal study of cognitive impairment following radiation therapy for locally advanced head and neck cancer
局部晚期头颈癌放射治疗后认知障碍的多模式研究
- 批准号:
10197030 - 财政年份:2019
- 资助金额:
$ 25.4万 - 项目类别:
Multimodal study of cognitive impairment following radiation therapy for locally advanced head and neck cancer
局部晚期头颈癌放射治疗后认知障碍的多模式研究
- 批准号:
10430157 - 财政年份:2019
- 资助金额:
$ 25.4万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant














{{item.name}}会员




